Rigel Pharmaceuticals, Inc.
RIGL
$26.55
$0.602.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.00% | 79.24% | 105.77% | 70.30% | 54.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.15% | 79.13% | 105.62% | 70.16% | 54.71% |
| Cost of Revenue | 25.91% | 26.91% | 60.04% | 63.61% | 32.86% |
| Gross Profit | 75.86% | 95.49% | 119.92% | 72.22% | 62.91% |
| SG&A Expenses | 2.51% | 4.56% | 4.93% | 5.51% | 6.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.85% | 10.24% | 17.24% | 17.82% | 12.89% |
| Operating Income | 418.63% | 1,151.72% | 1,259.76% | 379.25% | 212.57% |
| Income Before Tax | 563.33% | 2,846.02% | 796.57% | 292.53% | 173.20% |
| Income Tax Expenses | -27,931.67% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1,999.08% | 2,819.35% | 787.33% | 287.75% | 169.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,999.08% | 2,819.35% | 787.33% | 287.75% | 169.69% |
| EBIT | 418.63% | 1,151.72% | 1,259.76% | 379.25% | 212.57% |
| EBITDA | 384.03% | 962.78% | 1,542.22% | 420.83% | 230.45% |
| EPS Basic | 1,947.01% | 2,798.08% | 775.29% | 285.20% | 168.47% |
| Normalized Basic EPS | 552.52% | 2,825.48% | 784.42% | 280.75% | 169.17% |
| EPS Diluted | 1,856.73% | 2,814.65% | 760.73% | 281.56% | 165.85% |
| Normalized Diluted EPS | 539.26% | 2,773.19% | 774.34% | 278.16% | 167.97% |
| Average Basic Shares Outstanding | 2.31% | 1.81% | 1.43% | 1.22% | 1.05% |
| Average Diluted Shares Outstanding | 6.47% | 4.72% | 2.88% | 2.28% | 1.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |